First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience

INTRODUCTION: Clinical trial data has shown pazopanib to be non-inferior in overall survival (OS) compared to sunitinib as first-line treatment for metastatic renal cell carcinoma (mRCC). The purpose of this study was to evaluate outcomes and compare dose-modifying toxicities of mRCC patients treate...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Can Urol Assoc J
Main Authors: Lalani, Aly-Khan A., Li, Haocheng, Heng, Daniel Y.C., Wood, Lori, Kalirai, Austin, Bjarnason, Georg A., Sim, Hao-Wen, Kollmannsberger, Christian K., Kapoor, Anil, Hotte, Sebastien J., Vanhuyse, Marie, Czaykowski, Piotr, Reaume, M. Neil, Soulieres, Denis, Venner, Peter, North, Scott, Basappa, Naveen S.
Format: Artigo
Jezik:Inglês
Izdano: Canadian Medical Association 2017
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5434501/
https://ncbi.nlm.nih.gov/pubmed/28515811
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.4398
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki